Research Analysts Issue Forecasts for ResMed Q1 Earnings

ResMed Inc. (NYSE:RMD - Free Report) - Research analysts at William Blair lowered their Q1 2026 earnings per share (EPS) estimates for ResMed in a note issued to investors on Thursday, April 24th. William Blair analyst M. Andrew now anticipates that the medical equipment provider will post earnings of $2.45 per share for the quarter, down from their previous forecast of $2.66. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. William Blair also issued estimates for ResMed's Q2 2026 earnings at $2.57 EPS.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. The company had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.28 billion. ResMed had a return on equity of 26.17% and a net margin of 25.34%. ResMed's revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.13 earnings per share.

Other equities analysts also recently issued research reports about the stock. Piper Sandler lowered their price target on shares of ResMed from $260.00 to $248.00 and set a "neutral" rating on the stock in a report on Thursday, April 24th. The Goldman Sachs Group initiated coverage on shares of ResMed in a report on Thursday, January 16th. They issued a "buy" rating on the stock. Morgan Stanley initiated coverage on shares of ResMed in a report on Wednesday, March 19th. They issued an "overweight" rating and a $280.00 target price on the stock. Royal Bank of Canada boosted their target price on shares of ResMed from $247.00 to $255.00 and gave the stock a "sector perform" rating in a report on Thursday, April 24th. Finally, KeyCorp set a $274.00 target price on shares of ResMed in a report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ResMed has a consensus rating of "Moderate Buy" and an average price target of $258.83.

ResMed Stock Performance

ResMed stock traded down $2.50 during mid-day trading on Friday, reaching $235.24. 281,381 shares of the stock traded hands, compared to its average volume of 1,009,088. The business's 50-day moving average is $222.00 and its 200-day moving average is $233.98. The stock has a market capitalization of $34.55 billion, a PE ratio of 27.77, a price-to-earnings-growth ratio of 1.53 and a beta of 0.75. ResMed has a 12-month low of $179.42 and a 12-month high of $263.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Global X Japan Co. Ltd. grew its holdings in shares of ResMed by 121.4% in the first quarter. Global X Japan Co. Ltd. now owns 124 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Colonial Trust Co SC grew its holdings in shares of ResMed by 6,250.0% in the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 125 shares during the last quarter. Optiver Holding B.V. bought a new position in shares of ResMed in the fourth quarter worth about $33,000. Golden State Wealth Management LLC grew its holdings in shares of ResMed by 384.8% in the first quarter. Golden State Wealth Management LLC now owns 160 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 127 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its holdings in shares of ResMed by 1,000.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock worth $38,000 after purchasing an additional 150 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the transaction, the director now owns 77,218 shares in the company, valued at $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kaushik Ghoshal sold 9,113 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the transaction, the insider now owns 9,725 shares in the company, valued at $2,289,265. This trade represents a 48.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,013 shares of company stock worth $11,298,816 over the last quarter. Insiders own 0.71% of the company's stock.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's dividend payout ratio (DPR) is 23.79%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.